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Early progressive pulmonary arterial hypertension (PAH) is often observed in
patients with heterotaxy/polysplenia especially who have an intracardiac systemic-
to-pulmonary shunt. However, its etiology is uncertain and its management is not
well established. There was only a Japanese report about PAH in consecutive
patients with heterotaxy/polysplenia syndrome [1]. They seemed to develop pul-
monary vascular obstructive disease earlier and more severe than expected, even in
cases with only pre-tricuspid systemic-to-pulmonary shunt although more detailed
analysis is required.
Improved understanding and studies about the molecular genetics of heterotaxy
syndrome indicate that this disease can be caused by single gene mutations. Genes
currently implicated in human heterotaxy syndrome include ZIC3, LEFTYA, CRYP-
TIC, and ACVR2B [2]. The establishment of left-right asymmetry is regulated by a
number of developmental signaling pathways including the notch, which mediate
nodal expression surrounding the node [3]. Nodal, a growth regulator produced by
the node, is a signaling molecule belonging to the transforming growth factor
(TGF)-β superfamily that plays a variety of roles in the early development
[4]. Mouse nodal acts through type I (ALK-4, 5, and 7) and type II (ACVR2B)
receptors of the TGF-β superfamily. Ligand activation of the receptors requires one
or more co-receptors, Cryptic and Cripto. Lefty-1 (homologue of LEFTYA) is a
nodal antagonist that is expressed in medial left lateral plate mesoderm [5].
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The mutation in BMPR2, which encodes type II receptor of the bone morpho-
genic protein (BMP), is a well-known genetic cause of PAH [6]. BMP is also
belonging to the TGF-β superfamily. Although there has been no report that
describes the association between PAH and mutation of genes implicated in
heterotaxy syndrome, they might have some effect on the signaling pathway
downstream of BMP and, consequently, be relevant to the pulmonary vascular
pathogenesis in progressive PAH.
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